Biocontainment Research support services core

生物防护研究服务：摘要 NIAID 资助的 12 个区域生物防护实验室 (RBL) 均拥有 独特和互补的研究能力，以推进传染病和 生物防御研究。乔治梅森大学 (GMU) 的 RBL，也称为生物医学 研究实验室（BRL）专注于器官芯片的集成和开发 （OOC）遏制模型，以连接体外和动物模型测试的治疗和 疫苗产品筛选和评价。此外，GMU 拥有一整套 支持 BSL-3 病原体和选择剂气溶胶的先进研究仪器 小动物的暴露以及挑战的器官、组织和分子水平分析 研究。 GMU 的专业知识补充了这些遏制能力 蛋白质组学、代谢组学和纳米技术以及开发平台的跟踪记录 已从实验室过渡到市场的技术。 GMU 拟议的生物防护研究支持服务核心将包括 1) 微生理系统 (MPS) 核心和 2) 高级动物研究 (AAR) 核心。 MPS 平台将代表至少九个不同的器官系统，其中代表为 至少十二种优先病毒和细菌病原体的相关人源细胞类型。 伴随检测包括病原体定量、炎症检测限 将为每个模型开发感染情况下的负担和器官损伤。 核心中集成了额外的高通量片上器官 (OOC) 和类器官平台 将提供附加功能、通过多个平台验证结果以及加速 发现。 AAR 核心将集成一整套最先进的技术和 传染病专业知识，通过尖端技术加速对策开发 先导化合物优化、剂量、毒性筛选、安全性评估、功效、免疫的方法 调节和生物分布。 这些核心将配备 BRL 的研究科学家，以支持内部调查人员和 作为 RBL 网络以及制药和生物技术合作伙伴的资源 公司；联邦、州和地方机构；以及开展传染病研究的学术机构 疾病和生物防御研究和对策开发。

BIOCONTAINMENT RESEACRCH SERVICES: ABSTRACT Each of the twelve NIAID funded Regional Biocontainment Laboratories (RBLs) have distinguishing and complementary research capabilities to advance infectious disease and biodefense research. George Mason University’s (GMU)’s RBL, also known as the Biomedical Research Laboratory (BRL) has focused on the integration and development of organ-on-a-chip (OOC) models in containment to bridge in vitro and animal model testing for therapeutics and vaccine product screening and evaluation. Furthermore, GMU has a comprehensive suite of advanced research instrumentation to support BSL-3 pathogen and select agent aerosol exposures in small animals as well as organ, tissue, and molecular level analysis of challenge studies. These capabilities in containment are complemented by GMU’s expertise in proteomics, metabolomics, and nanotechnology as well as a track record of developing platform technologies that have transitioned from the bench to market. The proposed Biocontainment Research Support Services Core at GMU will include 1) a Microphysiological systems (MPS) core and 2) an Advanced Animal Research (AAR) core. The MPS platforms will represent at least nine different organ systems with representation by relevant human-derived cell types for at least twelve priority viral and bacterial pathogens. Accompanying assays including the limit of detection for pathogen quantification, inflammatory burden, and organ damage in the context of infection will be developed for each model. Additional high throughput organ-on-a-chip (OOC) and organoid platforms integrated in the core will provide added functionality, validation of results through multiple platforms, and accelerated discovery. The AAR core will integrate a comprehensive set of state-of-the-art technologies and infectious disease expertise to accelerate countermeasure development through cutting-edge approaches for lead optimization, dosing, toxicity screens, safety assessment, efficacy, immune modulation, and biodistribution. The cores will be staffed with research scientists in the BRL to support internal investigators and serve as a resource for the RBL network and partners from pharmaceutical and biotechnology companies; federal, state, and local agencies; and academic institutions conducting infectious disease and biodefense research and countermeasure development.